In February 2024, the food allergy world changed in a way that hadn't happened in decades. The FDA approved Xolair (omalizumab) as the first and only medicine specifically indicated to reduce the risk of allergic reactions from accidental food exposure. For families in Burbank, Glendale, Pasadena, and across the Los Angeles area who have spent years managing food allergies through avoidance and EpiPens, this was something new entirely: a regularly administered medicine designed to make accidental exposure less dangerous.

A year later, in March 2025, the second piece of news arrived. The National Institutes of Health-sponsored OUtMATCH study released the first head-to-head comparison of Xolair against multi-allergen oral immunotherapy — and Xolair came out ahead, both on efficacy and on side effect profile, for the specific population studied.

So what is Xolair, exactly? How does it work? Who does it help? How does it compare to oral immunotherapy (OIT), which has been the leading treatment option for years? And — practically — how do you know if your child is a candidate? At the Los Angeles Food Allergy Institute, our Burbank-based team led by Dr. Krikor Manoukian has been treating food allergies with Xolair, with OIT, and with both in combination. This guide walks through what we tell families during their initial consultation.

What Xolair Is, and What It Actually Does

To understand Xolair, you have to understand what's happening inside the body during an allergic reaction. When someone with a peanut allergy eats peanut, the protein binds to a specific antibody called IgE that's sitting on the surface of mast cells throughout the body. That binding triggers the mast cells to release histamine and other chemicals — and that's the cascade that causes hives, swelling, breathing problems, and in serious cases, anaphylaxis.

Xolair is a monoclonal antibody. Its job is straightforward: it binds to IgE in the bloodstream before the IgE can attach to the mast cells. With less IgE available to trigger the allergic cascade, accidental exposure to a food allergen produces a smaller reaction — or, often, no significant reaction at all.

Xolair doesn't cure the allergy. The body still produces IgE; the allergy is still there. What Xolair does is dramatically raise the threshold at which a reaction occurs. In the clinical trial that led to the FDA approval, after 16 to 20 weeks of treatment, 68% of patients on Xolair could consume roughly six times more peanut without a moderate or severe reaction than they could before treatment. Five percent of patients on placebo could do the same. The gap is substantial.

Who Xolair Is Approved For

The FDA approval covers a much wider population than most food allergy treatments. Xolair is approved for adults and children one year of age and older with IgE-mediated food allergy. That's a meaningful detail — most other food allergy interventions have an age floor of two, four, or higher. Xolair starts at age one.

It's approved for one food allergy or for multiple food allergies at the same time. This matters enormously for the families we see who have children allergic to peanut and tree nut and sesame, or to milk and egg and wheat. With Xolair, the same injection addresses all of those at once, rather than requiring a separate desensitization protocol for each allergen.

There are real candidacy criteria. Xolair isn't appropriate for every patient — dosing is determined by body weight and serum IgE level, and some patients have IgE levels too high for current dosing tables. There are some medical contraindications. And Xolair doesn't replace your epinephrine auto-injector: patients on Xolair still avoid the foods they're allergic to, still carry their auto-injectors, and still treat any actual anaphylactic reaction the way they always have. Xolair reduces the risk of a serious reaction; it doesn't eliminate it.

What Xolair Treatment Actually Looks Like

Compared to OIT, Xolair is logistically simple. It's a subcutaneous injection — administered every two or four weeks, depending on the patient's dosing schedule. The dose is calculated based on body weight and total serum IgE. The first injection is given at the clinic; for many patients, subsequent injections can be administered at home after the healthcare provider determines they're a good candidate for self-injection.

Here's the structure most families experience at our Burbank clinic:

• Initial consultation and testing. Skin prick testing, blood testing for total IgE and component IgE levels, and a complete medical history. This is the same diagnostic foundation we'd use before starting any food allergy treatment.
• Candidacy review. We look at the test results, the dosing tables, the patient's age and weight, any other medical conditions, and the family's goals. Some families want maximum protection against accidental exposure; some are trying to expand what their child can safely eat; some are managing multiple allergens at once. The right treatment plan depends on the answer.
• First injection at the clinic. After the initial dose, patients are monitored for a period of time to make sure there are no acute reactions to the injection itself. The vast majority don't have any.
• Ongoing injections. Every two or four weeks. At the clinic, or — once cleared for it — at home.
• Follow-up visits. Periodic check-ins with the allergist to monitor effectiveness, review any changes, and confirm everything is going as expected.

There's no daily home dosing routine, no need to schedule activities around the dose, no exercise or shower restrictions in the hours after taking it. Compared to OIT, that's a meaningful quality-of-life difference for many families.

What 16 to 20 Weeks of Xolair Looks Like

The clinical trial data is worth understanding because it sets realistic expectations. After 16 to 20 weeks of treatment, here's what the FDA-approval study (published in the New England Journal of Medicine) showed:

• 68% of Xolair-treated patients could consume roughly six times more peanut without a moderate or severe reaction than they could before treatment.
• Similar protective effects were demonstrated for other common food allergens including milk, egg, and cashew.
• 5% of placebo-treated patients reached the same threshold.
• The most common side effects in patients with food allergy were injection site reactions and fever.

What does this look like in real life? It looks like a child who used to react to a fraction of a peanut now tolerating an accidental bite of a peanut-butter cookie at a birthday party without ending up in the emergency room. It looks like a family that used to refuse all restaurant food now being able to eat at most restaurants with reasonable precautions. It doesn't look like a child who can eat peanut butter sandwiches every day — Xolair isn't a cure, and avoidance is still the rule. What it does change is the size of the consequence when avoidance fails.

Xolair vs. OIT: What the OUtMATCH Study Found

The OUtMATCH study is one of the most important pieces of food allergy research published in years, and the conversation it started is still unfolding. Sponsored by the National Institute of Allergy and Infectious Diseases, the study ran across 10 clinical sites in the United States and was led by Johns Hopkins and Stanford.

Stage 1 established that Xolair worked — that's the data that led to the FDA approval. Stage 2 went further: it directly compared Xolair to multi-allergen OIT. For the patients studied, Xolair was more effective at reducing allergic reactions and had fewer side effects than multi-allergen OIT.

That finding is important, but it doesn't mean Xolair is "better" than OIT in every situation. The reason: Xolair and OIT do different things.

• Xolair is a maintenance medication. As long as a patient takes it, their risk of reaction from accidental exposure is significantly reduced. If they stop taking it, the protection wears off.
• OIT is a desensitization process. Through gradual exposure to the actual food, the immune system is trained to tolerate that food. Patients on OIT typically end up incorporating small amounts of the food into their daily routine to maintain that tolerance.

The right choice depends on what the family is trying to achieve. A family that wants their child to be able to eat the allergen regularly — to have peanut butter sandwiches, to share birthday cake without question — is usually thinking about OIT. A family that wants strong protection against accidental exposure but isn't focused on eating the allergen daily, or that has multiple allergens to manage at once, is often a great candidate for Xolair monotherapy. And many families end up benefiting from the combination of both.

Xolair Combined With OIT

This is one of the more interesting use cases, and it's where the combined therapy approach we offer at our Burbank clinic comes in. For some patients — particularly those with high-risk food allergies, multiple food allergies, or a history of severe reactions — Xolair can be used in combination with OIT to make the OIT process safer and faster.

Here's how that works. OIT involves slowly introducing the allergen at increasing doses. The challenge during OIT is reactions during dose escalation — the very process designed to build tolerance can itself trigger reactions. Xolair, by lowering the IgE-driven response, reduces the risk and severity of those reactions during OIT. That allows for faster dose escalation, fewer adverse events, and a higher likelihood of completing the desensitization process.

For some patients we see, this combination is the most appropriate path. For others, Xolair monotherapy is the better fit. For still others, OIT alone is exactly right. Which is the point of an actual clinical evaluation: there isn't a single correct answer, and any clinic that pushes every patient toward the same protocol probably isn't customizing.

The Insurance Reality for Xolair

This is where Xolair has a significant practical advantage. Because Xolair is an FDA-approved medication for the food allergy indication, most major insurance plans now provide coverage for it when prescribed by an allergist who documents medical necessity. That's a meaningfully different situation from much of OIT, where the procedures are covered but the program fees often aren't. We covered the full picture in our recent guide on OIT cost in the Los Angeles area.

A few practical points on insurance and Xolair:

• Prior authorization is usually required. The insurance company will want documentation of the diagnosis, the medical justification, and confirmation that the treatment plan fits the FDA-approved indication. Our team handles this.
• Manufacturer copay assistance is available. For families with eligible commercial insurance, the Xolair manufacturer offers a copay assistance program that significantly reduces out-of-pocket cost. For many families, this is the difference between Xolair being affordable and being out of reach.
• Coverage varies. Some plans cover Xolair with minimal copay. Some apply it to a specialty drug tier with higher cost share. The only way to know what your specific plan does is to verify.

During the initial consultation, we'll review your insurance situation, contact your plan to confirm coverage, and let you know the realistic out-of-pocket cost before any commitment.

How to Know If Your Child Is a Candidate

There's no single profile that defines a "Xolair candidate," but a few patterns describe the families who most often come out of an evaluation with Xolair as part of their plan:

• Children one year and older with diagnosed IgE-mediated food allergy.
• Families with multiple food allergies to manage at once — peanut and tree nut, or milk and egg and wheat — where treating each separately would be complicated or impractical.
• Families whose primary goal is reducing the risk of severe reactions from accidental exposure, rather than incorporating the food into daily eating.
• Patients who have tried OIT in the past and didn't tolerate the daily dose escalation process.
• Patients with a history of severe reactions, where the safety profile of Xolair offers something OIT alone may not.

The most honest answer is that candidacy is a clinical question, and the only way to get a reliable answer is through an evaluation. The good news is that the evaluation itself is straightforward: a consultation, the standard allergy testing your insurance typically covers, and a treatment-options conversation with our team.

The Bottom Line

Xolair is the most significant new option in food allergy treatment in years. For the right patient, it dramatically reduces the risk of serious reactions from accidental exposure, handles multiple allergens at once, fits into a manageable two-to-four-week injection schedule, and is increasingly covered by insurance. It isn't a cure, it doesn't replace your epinephrine, and it isn't right for every patient. But for many families across the Los Angeles area — particularly those with multiple food allergies or a history of severe reactions — it's the option worth understanding first.

If you're in Burbank, Glendale, Pasadena, Sherman Oaks, Studio City, North Hollywood, La Crescenta, or anywhere in the greater LA area, and you're trying to understand whether Xolair makes sense for your family, the next step is a candidacy assessment. We'll review the medical history, run the necessary testing, contact your insurance, and give you a clear, specific recommendation — Xolair, OIT, the combination, or none of the above. There's no obligation to move forward, and the assessment fits within the standard initial consultation insurance covers.

Book a free Xolair candidacy assessment with Dr. Manoukian and the LAFAI team →

This article reflects publicly available information about Xolair (omalizumab) as of 2026, including the February 2024 FDA approval, the OUtMATCH study findings published in 2024 and 2025, and the prescribing information published by Genentech and Novartis. It is educational and does not constitute medical advice. Xolair is a prescription medicine with specific indications, contraindications, and possible side effects, including a Boxed Warning. A clinical evaluation with a board-certified allergist is required to determine whether Xolair is appropriate for any individual patient.

‍